24 May 2013
Keywords: novartis, glivec, gets, eu, cml, gist, license
Article | 19 September 2005
Swiss pharmaceutical firm Novartis says that it has received European Union approval for increased dosage indications for its anticancer agent
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 September 2005
© 2013 thepharmaletter.com